| Name | Sabizabulin |
| Description | Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer. |
| In vitro | METHODS: BT474 and SKBR3 cells were treated with Sabizabulin (ABI-231) (4, 8, 12, 16 nM), and cell growth inhibition was measured by MTS assay.
RESULTS Sabizabulin (ABI-231) significantly inhibited the growth of BT474 and SKBR3 cells in a concentration-dependent manner with IC50 values of 9.07 and 8.18 nM, respectively, and had low cytotoxicity. [1] |
| In vivo | METHODS: Sabizabulin (ABI-231) (17 mg/kg/20 mg/kg, oral, three weeks) was used to treat BT474 xenograft/HCI-12 PDX model mice and its therapeutic effect was observed.
RESULTS Sabizabulin (ABI-231) significantly reduced the tumor volume and tumor wet weight of terminal BT474 xenograft mice, inhibited tumor growth and suppressed lung metastasis in HCI-12 PDX model mice. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (132.49 mM), Sonication is recommended.
|
| Keywords | VERU111 | Sabizabulin | ABI 231 | VERU 111 | ABI231 |
| Inhibitors Related | Flubendazole | Mebendazole | N-Phenylbenzylamine | T-900607 | 4-Isopropoxybenzoic acid | Oxfendazole | Thiabendazole | Methylene Blue | Methylene Blue trihydrate | Paclitaxel | Benproperine phosphate | 4'-Demethylepipodophyllotoxin |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
